Annovis Bio, Inc. (ANVS)
1.70
+0.01
(+0.59%)
USD |
NYSE |
Sep 02, 16:00
1.62
-0.08
(-4.71%)
After-Hours: 20:00
Annovis Bio Enterprise Value : 53.70M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 53.70M |
| September 01, 2026 | 53.28M |
| August 31, 2026 | 54.55M |
| August 28, 2026 | 54.55M |
| August 27, 2026 | 58.39M |
| August 26, 2026 | 57.11M |
| August 25, 2026 | 58.81M |
| August 24, 2026 | 55.83M |
| August 21, 2026 | 58.81M |
| August 20, 2026 | 57.54M |
| August 19, 2026 | 60.09M |
| August 18, 2026 | 57.96M |
| August 17, 2026 | 55.41M |
| August 14, 2026 | 60.09M |
| August 13, 2026 | 57.54M |
| August 12, 2026 | 57.96M |
| August 11, 2026 | 61.80M |
| August 10, 2026 | 61.80M |
| August 07, 2026 | 61.37M |
| August 06, 2026 | 60.52M |
| August 05, 2026 | 60.94M |
| August 04, 2026 | 60.94M |
| August 03, 2026 | 54.55M |
| July 31, 2026 | 55.83M |
| July 30, 2026 | 56.68M |
| Date | Value |
|---|---|
| July 29, 2026 | 53.70M |
| July 28, 2026 | 53.28M |
| July 27, 2026 | 52.42M |
| July 24, 2026 | 52.00M |
| July 23, 2026 | 55.83M |
| July 22, 2026 | 55.41M |
| July 21, 2026 | 55.83M |
| July 20, 2026 | 53.28M |
| July 17, 2026 | 55.41M |
| July 16, 2026 | 55.41M |
| July 15, 2026 | 57.96M |
| July 14, 2026 | 54.13M |
| July 13, 2026 | 56.26M |
| July 10, 2026 | 60.52M |
| July 09, 2026 | 64.35M |
| July 08, 2026 | 66.06M |
| July 07, 2026 | 63.08M |
| July 06, 2026 | 65.21M |
| July 02, 2026 | 63.50M |
| July 01, 2026 | 63.08M |
| June 30, 2026 | 60.52M |
| June 29, 2026 | 38.86M |
| June 26, 2026 | 34.87M |
| June 25, 2026 | 32.87M |
| June 24, 2026 | 34.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.097B |
| Alnylam Pharmaceuticals, Inc. | 35.44B |
| Anika Therapeutics, Inc. | 275.24M |
| Savara, Inc. | 978.85M |
| Vericel Corp. | 2.024B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.82M |
| Total Expenses (Quarterly) | 14.82M |
| EPS Diluted (Quarterly) | -0.395 |
| Earnings Yield | -105.4% |
| Normalized Earnings Yield | -106.47 |